Get started

Financials · CUE

Cue Biopharma Inc. (CUE) financials

For the twelve months ended Jun 30, 2026, Cue Biopharma Inc. reported $37.65M of revenue and -$164.11M of net income.

Revenue, TTM
$37.65M
Revenue growth, YoY
+354.4%
Net income, TTM
-$164.11M
Net margin
-435.8%
Free cash flow, TTM
-$50.17M
Cash
$17.39M
P/S
3.89
Market cap
$146.3M
Annual revenue$27.47M
FY2018FY2025
Annual net income-$26.60M
FY2017FY2025
Annual free cash flow-$21.86M
FY2017FY2025

CUE revenue and earnings growth

CUE revenueQ2 2026$7.88M

Quarter YoY
+166.7%
QoQ
+38.5%
FY YoY
+195.7%
5Y CAGR
+54.2%

CUE revenue was $7.88M in fiscal Q2 2026 (ended Jun 30, 2026), up 166.7% from a year earlier and up 38.5% from the prior quarter. For the full fiscal 2025 it was $27.47M, up 195.7% from fiscal 2024. Compound annual growth was +54.2% over 5 years. It rose in 5 of the last 7 fiscal years. Fiscal 2025 is the highest of the 8 fiscal years on file.

CUE net incomeQ2 2026-$153.07M

CUE net income was -$153.07M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.48M a year earlier. For the full fiscal 2025 it was -$26.60M, compared with -$40.67M in fiscal 2024.

CUE EPSQ2 2026-$24.14

CUE diluted EPS was -$24.14 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$8.40.

CUE free cash flowQ2 2026-$29.00M

CUE free cash flow was -$29.00M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.44M a year earlier. For the full fiscal 2025 it was -$21.86M, compared with -$36.40M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$27.47M$9.29M$5.49M$1.25M$14.94M$3.15M$3.46M$1.14M-
Research and development$37.74M$36.30M$40.80M$38.58M$41.35M$33.55M$27.49M$28.54M$18.90M
Selling, general and admin$16.24M$14.59M$16.68M$16.17M$17.31M$14.65M$12.74M$11.30M$4.33M
Operating income-$26.55M-$41.50M-$52.15M-$53.23M-$43.71M-$45.04M-$36.77M-$38.70M-$23.23M
Interest expense$100.0K$100.0K$100.0K$109.0K-----
Pre-tax income----$53.01M-$43.67M-$44.58M-$36.29M-$38.16M-$23.23M
Income tax$500.0K$0-$0$495.0K$206.3K$412.5K$825.0K-
Net income-$26.60M-$40.67M-$50.73M-$53.01M-$44.16M-$44.78M-$36.70M-$38.98M-$23.23M
EPS, basic-$8.40-$21.60-$33.30-$44.70-$42.30-$46.80-$49.80-$58.20-$64.80
EPS, diluted-$8.40-$21.60-$33.30-$44.70-$42.30-$46.80-$49.80-$58.20-$64.80
Diluted shares3.2M1.9M1.5M1.2M1.0M956,287.5734,726.4671,135.5357,748.3

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$27.14M$22.46M$48.51M$51.61M$64.37M$74.87M$44.29M$20.80M$63.53M
Receivables$5.55M$945.0K$1.70M$57.0K$3.14M$1.42M$754.9K--
Current assets$36.98M$25.14M$51.45M$77.19M$68.47M$87.53M$61.02M$40.61M$65.07M
Total assets$42.21M$32.19M$61.53M$91.28M$83.40M$99.53M$71.61M$45.36M$66.95M
Current liabilities$13.49M$13.69M$17.08M$11.55M$12.79M$16.32M$11.66M$6.22M$5.35M
Short-term debt-$37.0K$4.00M$2.00M-----
Long-term debt-$0$4.20M$8.04M$0----
Total debt-$37.0K$8.20M$10.04M$0----
Total liabilities$15.78M$14.69M$24.45M$25.60M$17.91M$20.62M$17.02M$11.39M$5.35M
Shareholders' equity$26.43M$17.50M$37.09M$65.68M$65.49M$78.91M$54.58M$33.97M$61.61M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$21.69M-$36.33M-$39.96M-$41.81M-$38.84M-$32.49M-$30.80M-$26.41M-$12.14M
Capital expenditures$177.0K$66.0K$0$171.0K$913.0K$595.3K$46.4K$1.85M$1.03M
Free cash flow-$21.86M-$36.40M-$39.96M-$41.98M-$39.75M-$33.09M-$30.84M-$28.27M-$13.17M
Investing cash flow$75.0K$32.0K$25.00M-$24.61M$9.11M$4.46M$3.45M-$20.35M-$1.20M
Financing cash flow$26.29M$10.24M$11.86M$53.66M$19.23M$58.61M$50.79M$4.18M$62.00M
Share repurchases--$0$200.0K$750.1K$271.1K$91.0K--
Stock-based compensation$4.74M$6.85M$8.18M$9.50M$11.52M$10.48M$6.52M$7.17M$2.78M
Depreciation and amortization$958.0K$397.0K$556.0K$922.0K$1.26M$1.06M$810.8K$760.0K-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY195.7%69.2%341.0%-91.7%373.7%-8.8%202.7%--
Operating margin-96.7%-446.9%-949.9%-4275.1%-292.6%-1428.0%-1063.2%-3386.7%-
Net margin-96.9%-438.0%-924.1%-4257.8%-295.6%-1419.8%-1061.2%-3411.5%-
Free cash flow margin-79.6%-391.9%-727.9%-3371.6%-266.0%-1049.0%-891.9%-2473.8%-
Return on equity-100.6%-232.4%-136.8%-80.7%-67.4%-56.8%-67.2%-114.7%-37.7%
Return on assets-63.0%-126.4%-82.5%-58.1%-53.0%-45.0%-51.3%-85.9%-34.7%
Current ratio2.741.843.016.685.355.365.246.5312.17
Debt to equity-0.000.220.150.00----

Source: XBRL data Cue Biopharma Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported May 14, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CUE peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CUE$37.65M+354.4%-$164.11M-435.8%$146.3M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

CUE FAQ

7 questions
  • What is CUE revenue?
    Cue Biopharma Inc. (CUE) reported $37.65M of revenue for the twelve months ended Jun 30, 2026. That is up 354.4% from the year before. Revenue for fiscal 2025 was $27.47M.
  • Is CUE profitable?
    No. Cue Biopharma Inc. reported a net loss of $164.11M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does CUE have?
    Cue Biopharma Inc. reported $17.39M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CUE revenue growing?
    Cue Biopharma Inc.'s revenue changed +195.7% in fiscal 2025, to $27.47M. Its compound annual growth rate was +54.2% over 5 years.
  • What is CUE free cash flow?
    Cue Biopharma Inc. generated -$50.17M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$50.05M less capital expenditures.
  • When did CUE last report financial results?
    The latest statements here come from Cue Biopharma Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this CUE financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cue Biopharma Inc. files with the SEC. It is provided for information only and is not investment advice.